This early study tests whether combining a low-dose steroid with the drug ruxolitinib can better control grade II acute graft-versus-host disease (GVHD) after a stem cell transplant. GVHD occurs when donor immune cells attack the recipient's body. The trial includes 30 people wit…
Phase: PHASE1 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC